Clinical Research Directory

Inclusion Criteria: * Age 18 - 70 * Signed informed consent. * Hematologic malignancy or disorder requiring allogeneic hematopoietic cell transplantation * Adequate vital organ function: 1. Left ventricular ejection fraction (LVEF) ≥ 50% 2. Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 50% of predicted values on pulmonary function tests 3. Transaminases (aspartate aminotransferase \[AST\], aspartate aminotransferase \[ALT\]) \< 3 times upper limit of normal values 4. Creatinine clearance ≥ 50 cc/min. * Performance status: Karnofsky Performance Status Score ≥ 70%. * HCT donor is at least 8/8 (matched at HLA-A, -B, -C, -DRB1) matched with the recipient * PBSC (peripheral blood mobilized stem cells) as graft source * Fully myeloablative, reduced-toxicity ablative, or reduced-intensity conditioning regimens. If melphalan is part of the conditioning regimen, dose must be at least 75mg/m\^2 Exclusion Criteria: * Active infection not controlled with appropriate antimicrobial therapy * Human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection * Anti-thymocyte globulin (ATG) as part of the conditioning regimen or GVHD prophylaxis * Pregnant or nursing women * Subjects of childbearing age unwilling to use an effective birth control method or refrain from sexual intercourse until 15 weeks after last dose of study drug * Non-myeloablative conditioning regimens or conditioning regimens that use less than 75mg/m\^2 of melphalan * Prior allogeneic transplant * Non-malignant blood disorders (e.g. sickle cell disease, aplastic anemia) * Positive screening test for tuberculosis